Outlook Therapeutics, Inc.

DB:41O Stock Report

Market Cap: €75.6m

Outlook Therapeutics Valuation

Is 41O undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 41O when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate 41O's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate 41O's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 41O?

Key metric: As 41O barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 41O. This is calculated by dividing 41O's market cap by their current book value.
What is 41O's PB Ratio?
PB Ratio-2.9x
Book-US$28.99m
Market CapUS$87.26m

Price to Book Ratio vs Peers

How does 41O's PB Ratio compare to its peers?

The above table shows the PB ratio for 41O vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average27.7x
2INV 2invest
0.7xn/a€62.9m
8V8 Genetic Analysis
1.6xn/a€43.5m
20B Biomark Diagnostics
107.9xn/a€35.5m
HF00 Respiratorius
0.6xn/a€18.9m
41O Outlook Therapeutics
n/a40.23%€87.3m

Price-To-Book vs Peers: 41O has negative equity and a Price-To-Book Ratio (-2.9x) compared to the peer average (27.7x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does 41O's PB Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
MDG1 Medigene
0.1x14.15%US$2.07m
0C1 Atreca
0.2x4.34%US$1.85m
41O is unprofitableIndustry Avg. 2.9xNo. of Companies7PB00.81.62.43.24+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 41O has negative equity and a Price-To-Book Ratio (-2.9x) compared to the European Biotechs industry average (3x).

Price to Book Ratio vs Fair Ratio

What is 41O's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

41O PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-2.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 41O's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 41O forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.62
€3.55
+473.32%
62.23%€5.12€0.43n/a3
Jun ’27€0.63
€3.55
+468.73%
62.23%€5.12€0.43n/a3
May ’27€0.21
€3.55
+1,608.94%
62.23%€5.12€0.43n/a3
Apr ’27€0.17
€3.64
+2,077.15%
62.23%€5.24€0.44n/a3
Mar ’27€0.35
€4.56
+1,200.98%
86.11%€8.49€0.42n/a4
Feb ’27€0.39
€4.59
+1,067.91%
86.11%€8.54€0.43n/a4
Jan ’27€1.64
€5.73
+249.11%
72.86%€11.03€0.85n/a4
Dec ’26€1.48
€5.32
+260.93%
74.51%€11.07€0.85n/a4
Nov ’26€1.08
€5.32
+392.94%
74.51%€11.07€0.85n/a4
Oct ’26€0.87
€5.32
+514.40%
74.51%€11.07€0.85n/a4
Sep ’26€0.69
€7.05
+917.00%
94.43%€17.95€0.85n/a4
Aug ’26€1.61
€7.30
+353.72%
76.64%€17.84€2.55n/a5
Jul ’26€1.33
€7.40
+455.84%
76.64%€18.08€2.58n/a5
Jun ’26€1.37
€8.09
+488.63%
76.99%€21.18€2.65€0.636
May ’26€1.32
€9.13
+594.22%
70.24%€21.91€2.74€0.216
Apr ’26€1.16
€9.56
+723.71%
70.24%€22.93€2.87€0.176
Mar ’26€1.32
€9.56
+623.86%
70.24%€22.93€2.87€0.356
Feb ’26€1.93
€15.68
+712.44%
68.15%€31.68€2.88€0.396
Jan ’26€1.90
€23.84
+1,154.88%
45.43%€36.53€8.65€1.645
Dec ’25€1.56
€27.92
+1,689.86%
49.85%€50.16€8.52€1.486
Nov ’25€5.35
€36.45
+581.32%
22.39%€48.91€27.68€1.086
Oct ’25€4.88
€33.82
+592.97%
25.74%€47.89€22.59€0.877
Sep ’25€6.55
€33.61
+413.08%
26.36%€47.95€22.62€0.697
Aug ’25€7.10
€35.55
+400.65%
29.80%€55.50€23.13€1.617
Jul ’25€6.75
€35.55
+426.61%
29.80%€55.50€23.13€1.337
Jun ’25€6.65
€35.55
+434.53%
29.80%€55.50€23.13€1.377
€3.67
Fair Value
83.1% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 15:28
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Outlook Therapeutics, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets